Ascletis Pharma has become the first company to seek to list (PDF) in Hong Kong under the exchange’s new, more relaxed rules on biotech IPOs. The antiviral disease specialist will use the cash to win approvals for hepatitis C drugs licensed from Roche and Presidio Pharmaceuticals.
With a view of gathering mHealth data through a wearable from over 800 people with Parkinson’s disease, a project has been unveiled by the Michael J Fox Foundation which has been doing pioneering work in Parkinson’s disease.
According to reports, the biotechnology company Abpro has rescheduled its $96 million IPO, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year.
The team is focusing to make Alex, the voice assistant, more convenient and useful in the health-care sector, which requires regulations and data privacy set by the HIPAA – Health Insurance Portability and Accountability Act. The experts are aiming to work on diabetes management, assistance for mother, infants and the elderly.
Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence information contained in soil, today announced that it has formed a strategic drug discovery collaboration with Genentech, a member of the Roche Group.
The Government of the Democratic Republic of the Congo declared a new outbreak of Ebola virus disease (EVD) in Bikoro in Equateur Province today (8 May). The outbreak declaration occurred after laboratory results confirmed two cases of EVD.
AstraZeneca is back at it again with asset sales. The company, which has taken some flak for a series of deals to offload asset rights, inked an agreement with Luye Pharma for legacy antipsychotic Seroquel and an extended-release version.
Mayo Clinic researchers found success with an mHealth app - EpiFinder, which can diagnose Epilepsy (A disruption in which nerve cell activity in the brain is disturbed, causing seizures). During recent research conducted at Mayo Clinic, the Epifinder app recognized epilepsy in almost 87percent of the cases.
US regulators are undertaking a priority review of Roche unit Genentech’s PD-L1 inhibitor Tecentriq, in combination with Avastin and standard chemotherapy for some patients with lung cancer.
Today, Digital behavioral health company, Lyra Health announced that it has raised $45 million in Series B funding in a new financing round including Tenaya Capital, Glynn Capital, Crown Ventures, and Casdin Capital, as well as returning funders Greylock Partners, Venrock, and Providence Ventures.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.